研究者詳細 - 藤井　伸治

論文 - 藤井　伸治

分割表示 165 件中 121 - 140 件目／全件表示 >>

慢性C型肝炎ウイルス感染症の血清AFP値を除鉄療法は改善する査読

(木村文昭, 三島康男, 重戸伸幸, 福田智子, 山原茂裕, 佐原亜衣, 松村正,) 藤井伸治, 谷本光音

日本老年医学会雑誌 51 ( 3 ) 293 - 293 2014年5月

Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group. 査読

Fujii N, (Nakase K, Asakura S, Matsuo K, Nawa Y, Sunami K), Nishimori H, Matsuoka K, Kondo E, Maeda Y, Shinagawa K, (Hara M), Tanimoto M.

Int J Hematol 99 ( 5 ) 644 - 651 2014年5月

Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease. 査読

Sugiyama H, Maeda Y, Nishimori H, Yamasuji Y, Matsuoka K, Fujii N, Kondo E, Shinagawa K, Tanaka T, Takeuchi K, Teshima T, Tanimoto M.

Biol Blood Marrow Transplant 20 ( 2 ) 183 - 191 2014年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

Chronic graft-versus-host disease (GVHD) remains a major late complication of allogeneic bone marrow transplantation (BMT). In a previous study, impaired thymic negative selection of the recipients permitted the emergence of pathogenic T cells that cause chronic GVHD using MHC class II-deficient (H2-Ab1 KO) B6 into OH model and CD4(+) T cells isolated from chronic GVHD mice caused chronic GVHD when administered into the secondary recipients. In this study, we evaluated the kinetics of regulatory T cell (Treg) reconstitution in wild type B6 into C3H model. After myeloablative conditioning, host Tregs disappeared rapidly, followed by expansion of Tregs derived from the donor splenic T cell inoculum. However, the donor splenic T cell derived Treg pool contracted gradually and was almost completely replaced by newly generated donor bone marrow (BM)-derived Tregs in the late post-transplantation period. Next, we compared the effects of cyclosporine (CSA) and mammalian target of rapamycin (mTOR) inhibitors on Treg reconstitution. Administration of CSA significantly impaired Treg reconstitution in the spleen and thymus. In contrast, BM-derived Treg reconstitution was not impaired in mTOR inhibitor-treated mice. Histopathological examination indicated that mice treated with GSA, but not mTOR inhibitors, showed pathogenic features of chronic GVHD on day 120. Mice treated with CSA until day 60, but not mTOR inhibitors, developed severe chronic GVHD followed by adoptive transfer of the pathogenic CD4(+) T cells isolated from H2-Ab1 KO into C3H model. These findings indicated that long-term use of CSA impairs reconstitution of BM-derived Tregs and increases the liability to chronic GVHD. The choice of immunosuppression, such as calcineurin inhibitor-free GVHD prophylaxis with mTOR inhibitor, may have important implications for the control of chronic GVHD after BMT.

DOI： 10.1016/j.bbmt.2013.11.018

CiNii Article

researchmap

新しい全自動型血液成分分離装置Spectra Optiaを用いた末梢血幹細胞採取-COBE Spectraと比較して- 査読

藤井敬子,藤井伸治,淺田騰,西森久和,狩山由貴,池田亮,浅野尚美,小郷博昭,岩月啓氏

日本輸血細胞治療学会誌 59 ( 6 ) 799 - 804 2014年1月

Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation. 査読国際誌

Asano T, Fujii N, Niiya D, Nishimori H, Fujii K, Matsuoka 1, Ichimura K, Hamada T, Kondo E, Maeda Y, Tanimoto Y, Shinagawa K, Tanimoto M.

Springerplus 3 3 - 3 2014年1月

Pre-transplant risk factors for cryptpgenic organizing pneumonia/brnchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. 査読

Nakasone H, Onizuka M, Suzuki N, Fujii N, Taniguchi S, Kakihana K, Ogawa H, Miyamura K, Eto T, Sakamaki H, Yabe H, Morishima Y, Kato K, Suzuki R, Fukuda T.

Bone Marrow Transplantation 1 - 7 2013年10月

Erdheim-Chester病が強く疑われた下垂体機能低下症の一例査読

三好智子,大塚文男,稲垣謙一,田中康司,越智可奈子,藤井一恭,藤井伸治,当真貴志雄,中村絵里,塚本尚子,武田昌也,三村由香里,小倉俊郎,景山甚郷,槇野博史

日本内分泌学会誌 89 ( Suppl. ) 21 - 23 2013年6月

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplant with T cells specific for minor histocompatibility antigens. 査読

Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR, Gooley TA, Brown ML, Koo KK, Rosinski KV, Ogawa S, Matsubara A, Appelbaum FR, Riddell SR.

Blood 115 3869 - 3878 2010年5月

Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation. 査読

SIgiura Y, Soga Y, Yamabe K, Tsutani S, Tanimoto I, Maeda H, Kokeguchi S, Fujii N, Ishimaru F, Tanimoto M, Nishimura F, Takashiba S.

Support Care Cancer 2010年5月

Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation 査読

Yuko Sugiura, Yoshihiko Soga, Kokoro Yamabe, Soichiro Tsutani, Ichiro Tanimoto, Hiroshi Maeda, Susumu Kokeguchi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Fusanori Nishimura, Shogo Takashiba

SUPPORTIVE CARE IN CANCER 18 ( 3 ) 395 - 398 2010年3月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：SPRINGER

The commercial saliva substitute OralbalanceA (R) has been reported to alleviate symptoms of postradiotherapy xerostomia in head and neck cancer patients. OralbalanceA (R) may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are in a severely compromised condition, and saliva substitute must not promote infection. We reported previously that OralbalanceA (R) has antimicrobial effects against microbial species detected during HCT in vitro. This study was performed to determine the in vivo effects of OralbalanceA (R) on oral mucosal total bacterial counts in patients undergoing HCT.
A total of 18 neutropenic patients undergoing HCT were enrolled in this study. Before and after 1 week of OralbalanceA (R) use, bacterial samples were obtained from patients by wiping an area of I center dot 1 cm on the buccal mucosa with sterilized cotton swabs. Total bacterial counts of the obtained samples were examined by quantitative polymerase chain reaction amplification of the bacterial 16S ribosomal RNA gene. As controls, bacterial samples were also obtained from ten healthy subjects, and total bacterial counts were examined.
No significant increase in bacterial count was observed with use of OralbalanceA (R). None of the patients showed bacterial counts above the range found in healthy controls after using OralbalanceA (R).
In neutropenic patients undergoing HCT, OralbalanceA (R) did not increase the total counts of oral mucosal bacteria beyond the range found in healthy controls. Oral care using OralbalanceA (R) may alleviate the symptoms induced by hyposalivation without promoting infection.

DOI： 10.1007/s00520-009-0789-x

Web of Science

PubMed

researchmap

A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. 査読

Turtle CJ, Swanson HM, Fujii N, Estey EH, Riddell SR.

Immunity 31 834 - 834 2009年11月

Efficacy and feasibility of IDEA therapy for refractory or relapsed non-hodgkins lymphoma 査読国際誌

Nishimori H, Fujii N, Maeda Y, Matsuoka K, Takenaka K, Shinagawa K, Ikeda K, Matsuo K, Harada M, Tanimoto M

Anticancer Research 29 ( 5 ) 1749 - 54 2009年5月

The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma : a propensity score matching analysis 査読

Nishimori H, Matsuo K, Maeda Y, Nawa Y, Sunami K, (Togitani K), Takimoto H, Hiramatsu Y, Kiguchi T, Yano T, Yamane H, Tabayashi T, Takeuchi M, Makita M, Sezaki N, Yamasuji Y, Sugiyama H, (Tabuchi T), Kataoka I, Fujii N, Ishimaru F, Shinagawa K, Ikeda K, Hara M, (Yoshino T), Tanimoto M

Int J Hematol 89 ( 3 ) 326 - 331 2009年4月

Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation 査読

Hiramatsu Y, Maeda Y, Fujii N, Saito T, Nawa Y, Hara M, Yano T, Asakura S, Sunami K, Tabayashi T, Miyata A, Matsuoka K, Shinagawa K, Ikeda K, Matsuo K, Tanimoto M

Int J Hematol 88 ( 5 ) 588 - 595 2008年12月

Evaluation of xerostomia in hematopoietic cell transplantation by a simple capacitance method device. 査読国際誌

Sugiura Y, Soga Y, Nishide S, Kono K, Takahashi K, Fujii N, Ishimaru F, Tanimoto M, Nishimura F, Takashiba S.

Support Care Cancer 16 ( 10 ) 1197 - 200 2008年10月

C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. 査読

Tykodi SS, Fujii N, Vigneron N, Lu SM, Mito JK, Miranda MX, Chou J, Voong LN, Thompson JA, Sandmaier BM, Cresswell P, Van den Eynde BJ, Riddell SR, Warren EH.

Clinical Cancer Research 2008年8月

DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells 査読

Rosinski KV, Fujii N, Mito JK, Koo KK, Xuereb SM, Sala-Torra O, Gibbs JS, Radich JP, Akatsuka Y, Van den Eynde BJ, Riddell SR, Warren EH.

Blood 2008年5月

Anitmicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. 査読国際誌

Sugiura Y, Soga Y, Tanimoto I, Kokeguchi S, Nishide S, Kono K, Takahashi K, Fujii N, Ishimaru F, Tanimoto M, Yamabe K, Tsutani S, Nishimura F, Takashiba S.

Support Care Cancer 16 ( 4 ) 421 - 4 2008年4月

Appearance of multidrug-resistant opportunistic bacteria on the gingiva during leukemia treatment. 査読国際誌

Soga Y, Saito T, Nishimura F, Ishimaru F, Mineshiba J, Mineshiba F, Takaya H, Sato H, Kudo C, Kokeguchi S, Fujii N, Tanimoto M, Takashiba S.

Support Care Cancer 79 ( 1 ) 181 - 6 2008年1月

Predominant Infiltration of Monocytes in Chronic Graft-Versus-Host Disease 査読

Namba Noriko, Shinagawa Katsuji, Fujii Nobuharu, Maeda Yoshinobu, Ishimaru Fumihiko, Ikeda Kazuma, Matsui Toshimitsu, Tanimoto Mitsune, Katayama Yoshio

Transplantation 83 ( 2 ) 220 - 224 2007年1月

　前のページ - 次のページ　

<藤井 伸治>

論文 - 藤井 伸治

<藤井　伸治>

論文 - 藤井　伸治